
@EngBigData $SFLM A revival/comeback sure would be nice. It's surprising after two years, a new business hasn't jumped at the opportunity to take over a debt-free shell (as far as anyone can tell) with a fairly low float compared to other OTCs. It's just sitting there waiting for a new home.
English













